Stifel Financial’s Trillium Therapeutics Inc. TRIL Stock Holding History

Stifel Financial’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-106,900	Closed	-$1.88M	–	3532
2021 Q3	$1.88M	Buy	106,900 +25,250	+31%	+$295K	﹤0.01%	1623
2021 Q2	$792K	Buy	81,650 +29,450	+56%	+$277K	﹤0.01%	2269
2021 Q1	$561K	Buy	52,200 +11,100	+27%	+$137K	﹤0.01%	2406
2020 Q4	$605K	Buy	41,100 +30,800	+299%	+$444K	﹤0.01%	2202
2020 Q3	$146K	Buy	+10,300	New	+$103K	﹤0.01%	2687

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Stifel Financial's TRIL Position: Q4 2021 in Review

Stifel Financial sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 106,900 shares — an estimated $1.88M sold.

Stifel Financial first reported a position in TRIL in Q3 2020 and held it in 5 quarters. The position peaked at $1.88M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Stifel Financial reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Stifel Financial sold 106,900 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $1.88M.
Stifel Financial first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 5 quarters.
Stifel Financial's Trillium Therapeutics Inc. position peaked at $1.88M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Stifel Financial's 13F filing for Q4 2021, filed 14 Feb 2022.